SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following its latest update, which showcased substantial revenue growth and accelerating global expansion of its ANKTIVA cancer therapy, sparking community discussion around potential expedited regulatory approvals and a significant short squeeze opportunity amid high after-hours volatility.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is seeing intense trading and sharp declines despite broader energy sector rallies and surging crude oil prices driven by escalating Middle East tensions. The community is fiercely debating whether this extreme volatility stems from active dilution and market manipulation or is a massive shakeout positioning the low-float stock for a potential short squeeze, reminiscent of its historical explosive movements during geopolitical events.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending following its recent earnings report, which delivered a narrow beat and generally in-line guidance, sparking a heated community debate between those who view it as a leading cybersecurity platform poised to benefit from AI and rising geopolitical tensions, and others who contend its valuation remains excessively high despite analyst upgrades.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending following mixed reactions to its Q4 '26 earnings report, which saw a beat on revenue and EPS along with a $400M share repurchase program, yet offered weaker-than-expected FY2027 guidance. The community is divided between those buying the dip, citing AI integration and persistent buyout rumors, and bears concerned about slowing growth and the impact of AI competition on software companies.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a strong earnings beat and robust cash position, yet community discussion is overwhelmingly dominated by frustration over CEO Peter Greenleaf's continued lack of transparency regarding AUR200's clinical trial indications, fueling speculation of an imminent buyout amidst accusations of mismanagement.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics Inc. is trending following its transformative acquisition of Covelya Group, significantly expanding its global footprint in subsea technology and positioning it as a major supplier for defense and commercial sectors. The community is actively discussing potential short-term share dilution from a public offering against robust long-term growth potential and strategic partnerships within the burgeoning underwater robotics sector.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging amid a flurry of positive developments, including a significant settlement in its patent dispute with Arbutus Biopharma and Genevant, the FDA's reversal to review its seasonal flu vaccine, and a European recommendation for its COVID-19/flu combination shot, driving strong community optimism for its pipeline and a potential short squeeze.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging as escalating Middle East tensions halt Qatar's LNG production and disrupt the Strait of Hormuz, driving global natural gas prices dramatically higher. This geopolitical "perfect storm," combined with a strong earnings beat and a favorable legal outcome against Shell, positions the company as a key beneficiary, fueling community discussion around potential short squeezes and its undervalued status.

Ross Stores, Inc. engages in the operation of off-price retail apparel and home accessories stores. Its products include branded and designer apparel, accessories, footwear, and home fashions through the Dress for Less and dd's DISCOUNTS brands. The company was founded by Stuart G. Moldaw in 1957 and is headquartered in Dublin, CA.

Ross Stores, Inc.

Ross Stores is trending after reporting strong financial results, surpassing expectations for the recent quarter, and projecting solid sales and earnings growth for the upcoming fiscal years, alongside a significant share buyback program. The community is actively discussing whether these positive results and outlook justify the stock's current valuation, given broader retail market dynamics.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending due to preliminary Q4 financial results surpassing expectations, confirming profitability and strong product sales growth. This, alongside promising clinical data for its pipeline assets and an active biotech M&A landscape, fuels widespread community speculation about the company's significant undervaluation and potential for a strategic acquisition, despite persistent short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Fourth-quarter revenue came in at $27.3 million, below Wall Street’s estimates of $33.3 million, according to Fiscal.ai data.</li><li>H.C. Wainwright cut its price target on BigBear.ai to $6 from $8, citing lower sales estimates.</li><li>Cantor Fitzgerald reduced its price target to $5 from $6 and maintained a ‘Neutral’ rating.</li></ul>Shares of BigBear.ai Holdings Inc. (BBAI) were in the spotlight on Tuesday after a wave of bearish brokerage reactions to its fourth-quarter results and fiscal 2026 outlook weighed on investor sentiment.The company reported a 38% fall in fourth-quarter (Q4) revenue to $27.3 million, falling below Wall Street’s estimates of $33.3 million, according to Fiscal.ai data. BigBear.ai said the revenue decline was primarily due to lower volume on Army programs.The company posted a net loss of $5.8 million, or $0.01 per share, compared to consensus estimates of a loss of $0.05 per share.Looking ahead, BigBear.ai expects full-year 2026 revenue between $135 million and $165 million, implying around 17% growth at the midpoint compared with 2025 revenue of $128 million. Shares of <a href="https://stocktwits.com/symbol/BBAI">BigBear.ai Holdings</a> Inc. (BBAI) slid around 8% on Tuesday.<h2 class="st-heading-2">Analyst Cites FY2026 Sales Estimate For Price Cut</h2>H.C. Wainwright cut its price target on BigBear.ai to $6 from $8 and kept a ‘Buy’ rating post the Q4 report, according to The Fly. The firm said recent balance sheet improvements offer greater flexibility to support future growth, but slashed the target due to lower sales estimates.Cantor Fitzgerald reduced its price target on BigBear.ai to $5 from $6 and maintained a ‘Neutral’ rating. The firm noted that while fourth-quarter results were solid, revenue declined 37.7% to $27.3 million, largely due to disruptions in certain Army contracts and broader federal shutdown-related headwinds.Over the last couple of months, BigBear.ai took steps to strengthen its balance sheet by significantly reducing its outstanding convertible debt. In January, the company called for the redemption of its 6.00% convertible senior secured notes due 2029 and said it expects to reduce total note-related debt from about $142 million to roughly $17 million.Separately, BigBear.ai also completed its $250 million cash acquisition of Ask Sage, a generative AI platform for defense and intelligence markets.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes.However, chatter has been largely bearish, with one user noting deteriorating earnings “despite a backlog that seemed to promise great results.”<stembedurl>https://stocktwits.com/Cerberus_79/message/646398153</stembedurl>Another bearish user expects the stock to “bleed slowly” and fall under $2. It is currently trading around $3.8.<stembedurl>https://stocktwits.com/nostoplosss/message/646397835</stembedurl>The stock has been under heavy selling pressure so far in 2026, slumping more than 32%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tbph-stock-slumps-theravance-misses-primary-endpoint-phase-3-study/cZdeSXwRIPL">TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The BigBear.ai Holdings Inc logo appears on a smartphone screen and as a background on a laptop screen in this photo illustration in Athens, Greece.

BBAI Stock Slides 8% – Analyst Flags Soft Sales Estimate, Retail Expects A Further 50% Slump In Share Price

Brokerages cut the stock’s price target after the company reported a 38% decline in fourth-quarter revenue.

Equity

TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint

TBPH company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.

<ul class="summary-bullets"><li>Aardvark voluntarily paused the HERO Phase 3 trial on Friday after a routine safety monitoring of a healthy volunteer found reversible cardiac effects.</li><li>Aardvark said it no longer expects to release HERO trial topline data in Q3 2026.</li><li>Stifel called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.”</li></ul>Shares of Aardvark Therapeutics (AARD) plummeted 4% in pre-market trading on Monday after a wave of bearish analyst downgrades following the company’s decision to pause its Phase 3 trial evaluating the treatment for hyperphagia in patients with Prader-Willi syndrome.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/AARD">AARD shares</a> could fall to their lowest levels since Apr. 9, 2025.On Friday, Aardvark said it voluntarily paused the HERO Phase 3 and related extension trials after a routine safety monitoring of a healthy volunteer found reversible cardiac effects at doses above the target therapeutic level.Aardvark said it no longer expects to release HERO trial topline data in the third quarter (Q3) of 2026 and will instead provide updated guidance in the second quarter.<h2 class="st-heading-2">Analyst Expresses Skepticism About The New Uncertainty</h2>Stifel downgraded Aardvark Therapeutics to ‘Hold’ from ‘Buy’ and reduced its price target to $6 from $24, according to The Fly. This represents a 52% downside to Friday’s closing price of $12.5. The brokerage called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.” It is “very hard to build confidence in what the path forward may look like,” Stifel added.Morgan Stanley downgraded Aardvark Therapeutics to ‘Equal Weight’ from ‘Overweight’ and significantly slashed its price target to $7 from $29, according to The Fly. While the brokerage still sees potential for ARD-101, it lowered its rating due to near-term uncertainties.RBC Capital said that timelines are likely to be significantly delayed as the Aardvark works with the FDA on next steps, adding a “layer of uncertainty” around the program. The brokerage downgraded the stock to ‘Sector Perform’ from ‘Outperform’ and cut its price target to $6 from $18.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>While retail sentiment on Stocktwits remained ‘extremely bullish,’ amid ‘extremely high’ message volumes, chatter was largely ‘bearish’.<img src="https://news.stocktwits-cdn.com/AARD_jpg_eaa4fec962.webp" alt="AARD.jpg">One user said the suspension of the trial was “one of the worst news.”<stembedurl>https://stocktwits.com/focafoca99/message/646219667</stembedurl>Another user expects the stock to decline to $3.<stembedurl>https://stocktwits.com/jojoraizza/message/646210388</stembedurl>The stock has lost around 56% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spy-falls-100-day-moving-average-oil-vix-middle-east-tensions/cZd33g2RIcH">SPY On Track To Fall Below 100-DMA For First Time In Nine Months – Retail Braces For Prolonged Volatility</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

<ul class="summary-bullets"><li>Searchlight and Abry will acquire all issued and outstanding shares of KORE common stock not already owned by them at an all-cash price of $9.25 per share.</li><li>This represents a premium of about 85% compared to KORE’s closing price on Thursday.</li><li>KORE stated that, post-acquisition, it will be taken private while continuing to focus on its current Internet of Things consumer product portfolio.</li></ul>KORE Group Holdings Inc. (KORE) stock ripped nearly 80% in Friday’s pre-market trade after the company announced that it has entered into a definitive agreement to be acquired by Searchlight Capital Partners and Abry Partners.KORE stated that Searchlight and Abry will acquire all shares of the company’s issued and outstanding common stock that they currently don’t own. The all-cash transaction is valued at nearly $726 million.Searchlight and Abry will acquire all issued and outstanding shares of KORE common stock not already owned by them at an all-cash price of $9.25 per share.This represents a premium of about 85% compared to KORE’s closing price on Thursday.<h2 class="st-heading-2">KORE To Be Taken Private</h2>KORE stated that, post-acquisition, it will be taken private while continuing to focus on its current Internet of Things consumer product portfolio. It expects the transaction to close in the third quarter (Q3) of 2026.“Both firms have an exceptional track record of helping their portfolio companies foster the growth and innovation required to be an industry leader with a loyal and satisfied customer base,” said KORE CEO Ron Totton.While Searchlight is a global investment firm with $18 billion in assets under management, Abry is a private equity firm managing about $16 billion across its funds.The two firms had sent a non-binding letter to KORE in November 2025 to acquire all of the company's shares they don’t already own for a cash consideration of $5 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/KORE">KORE Group</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels.One user on Stocktwits called the acquisition news very good, while adding that volumes could push the stock to $10, nearly doubling it from Thursday’s closing price.<stembedurl>https://stocktwits.com/Josema66/message/646080395</stembedurl><a href="https://stocktwits.com/symbol/KORE">KORE stock</a> is up 19% year-to-date and 116% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wbd-stock-double-downgrade-after-netflix-pulls-out-of-bidding-war-with-psky/cZTciKoRIT2">WBD Gets A Double Downgrade After Netflix Pulls Out Of Bidding War With Paramount Skydance — Here's What Analysts Said</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

KORE Stock Is Ripping Pre-Market Today After Company Agrees To A Deal To Take It Private

KORE stated that Searchlight and Abry will acquire all shares of the company’s issued and outstanding common stock that they currently don’t own in an all-cash transaction valued at nearly $726 million.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did NGNE Stock Surge 25% In Pre-Market Today?

The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome.

This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target 

<ul class="summary-bullets"><li>On a full-year basis, Cipher’s revenue of $223.9 million fell short of the market forecast of $249.7 million.</li><li>On February 20, the board of directors approved a corporate name change to Cipher Digital Inc. while retaining the same ticker.</li><li>On Monday, Canaan announced the acquisition of Cipher’s 49% stake in the ABC Projects joint venture in Texas for about $39.75 million.</li></ul>Shares of Cipher Digital Inc (CIFR) gained 2% in pre-market trading on Tuesday after the company reported fourth-quarter results that missed Wall Street expectations.Cipher’s fourth-quarter revenue came in at $60 million, significantly below the consensus estimates of $85.7 million, according to Fiscal.ai data. The company reported an adjusted net loss of $55 million for the quarter. Analysts had expected the company to earn $0.13 per share.On a full-year basis, Cipher’s revenue of $223.9 million fell short of the market forecast of $249.7 million.<h2 class="st-heading-2">Rebranded To Cipher Digital</h2>On February 20, the board of directors approved a corporate name change to Cipher Digital Inc while retaining the same ticker. It also completed three high-yield offerings to fund the construction of data centers at the Barber Lake and Black Pearl sites.During the quarter, the company also secured 600 MW of total contracted HPC capacity through two agreements, a 15-year, 300 MW lease with AWS and a 10-year, 300 MW lease with Fluidstack and Google.“Building on a transformative 2025, the fourth quarter reflected continued momentum as we advanced our evolution into a leading HPC data center development company. During the quarter, we upsized our initial lease with Fluidstack and Google and signed our first HPC lease with Amazon. In addition, we successfully executed multiple high-yield bond offerings to finance two of our existing HPC projects at Barber Lake and Black Pearl,” said Tyler Page, Chief Executive Officer.<h2 class="st-heading-2">Canaan Acquires Cipher’s ABC Projects Stake</h2>On Monday, Canaan Inc. (CAN) announced the acquisition of Cipher Digital’s 49% stake in the ABC Projects joint venture in Texas for about $39.75 million, paid in newly issued shares. The sites operate 120 MW of power capacity and support roughly 4.4 EH/s of hashrate.As part of the deal, Canaan also purchased 6,840 Avalon A15Pro mining rigs. The shares issued in the transaction are subject to a six-month lock-up period.The deal will help Cipher streamline its operations and accelerate its strategic transition to a HPC data center development company, it said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market fall, retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ a day earlier. <a href="https://stocktwits.com/symbol/CIFR">CIFR</a> was among the top trending tickers at the time of writing.<img src="https://news.stocktwits-cdn.com/CIFR_jpg_4537e1927a.webp" alt="CIFR.jpg">One user said the deals with Fluidstack and AWS will generate a “massive revenue increase”.<stembedurl>https://stocktwits.com/StockyMarciano/message/645700726</stembedurl>Another user noted the revenue miss and added, “technically just don't like the chart at the moment.”<stembedurl>https://stocktwits.com/Bullchart/message/645700714</stembedurl>Year-to-date, the stock has gained nearly 4%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/corning-glw-stock-record-high-price-target-hikes/cZRvDuPR4CR">GLW Stock On Track To Open At All-Time High – AI Data Centre Boom Spurs Price Target Hikes</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

CIFR Stock Is Gaining Retail Attention After Earnings Despite Revenue Miss – Here’s What Investors Are Watching 

Cipher’s fourth-quarter revenue came in at $60 million, significantly below the consensus estimates of $85.7 million, according to Fiscal.ai data.

Why Is CIFR Stock Gaining Retail Attention Today?  

<ul class="summary-bullets"><li>Palvella said the study met its key secondary endpoint and all four additional secondary endpoints.</li><li>In the Phase 3 SELVA study, QTORIN rapamycin was generally well tolerated.&nbsp;</li><li>The company plans to submit an NDA to the U.S. FDA in the second half of 2026.</li></ul>Shares of Palvella Therapeutics Inc (PVLA) jumped nearly 37% on Tuesday, after the company reported positive topline results from its Phase 3 SELVA study, potentially paving the way for a FDA submission.&nbsp;The company said its lead candidate, QTORIN 3.9% rapamycin anhydrous gel, met its primary endpoint, showing a statistically significant improvement on the Microcystic Lymphatic Malformation Investigator Global Assessment scale.&nbsp;The study also met its key secondary endpoint and all four additional secondary endpoints, each demonstrating statistical significance in patients with microcystic lymphatic malformations (MLM), a rare vascular condition. MLM is a benign, fluid-filled cyst that can form under the skin, often on the neck or the head.<h2 class="st-heading-2">QTORIN Rapamycin Was Well Tolerated</h2>In the Phase 3 SELVA study, QTORIN rapamycin was generally well tolerated. Of the 50 patients who started treatment, 70% reported side effects, most of which were mild or moderate. Four serious adverse events were reported, but investigators said they were not related to the drug. The most common treatment-related issues were mild skin reactions at the application site.88% of the patients completed the 24-week study. Nearly all eligible participants chose to continue treatment in the extension phase.Based on these results, the company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026, with potential U.S. approval expected in the first half of 2027, the firm added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ following the update, from ‘neutral’ a day earlier. Message volume on the platform was ‘extremely high’.<img src="https://news.stocktwits-cdn.com/PVLA_jpg_d1bfdadf88.webp" alt="PVLA.jpg">Year-to-date, the stock has gained around 16%&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did PVLA Stock Surge 37% Today?

The biotech company reported statistically significant Phase 3 data for QTORIN gel.

PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment 

<ul class="summary-bullets"><li>Atomera’s stock offering is at a discount of 40% when compared to the closing price on Friday.</li><li>The company stated that it intends to use the funds raised through the stock offering to meet its working capital requirements and other general corporate needs.</li><li>Atomera added that the stock offering is expected to close on or about Feb. 24, 2026.</li></ul>Atomera Inc. (ATOM) stock declined nearly 13% in Monday’s opening trade after the company announced the pricing of a new stock offering.Atomera announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share. This is at a discount of 40% from the stock’s closing price on Friday.<h2 class="st-heading-2">What Will Atomera Use The Funds For?</h2>Atomera stated in its announcement that it intends to use the funds raised through the stock offering to meet its working capital requirements and other general corporate needs.The company added that the stock offering is expected to close on or about Feb. 24, 2026.Atomera reported its fourth-quarter (Q4) results earlier this month, posting a loss of $0.14 per share, in line with Wall Street expectations. The company reported revenue of $0.05 million, while the consensus estimate was $0.1 million, according to Stocktwits data.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ATOM">Atomera</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.Despite Atomera’s share price decline, one bullish user said it's a buying opportunity.<stembedurl>https://stocktwits.com/BioRocket/message/645608846</stembedurl>Another user stated they’re surprised by Atomera’s stock offering, noting that the company didn't need cash.<stembedurl>https://stocktwits.com/DinoMcnuggets/message/645607759</stembedurl><a href="https://stocktwits.com/symbol/ATOM">ATOM stock</a> is up 217% year-to-date and 9% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palo-alto-networks-removed-from-wedbush-best-ideas-list/cZRtp2lR4ya">Palo Alto Networks Removed From Wedbush’s ‘Best Ideas List’ — Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Atomera Incorporated logo is seen displayed on a smartphone and pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

ATOM Stock Is Falling Today After Atomera Announces Stock Offering At A Deep Discount

The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.

<ul class="summary-bullets"><li>HYMC said it now holds 16.4 million gold ounces and 562.6 million silver ounces in the measured and indicated categories.</li><li>It reported increases in inferred mineral resources of 50% for gold and 38% for silver.</li><li>The company said it is continuing to evaluate a roasting process alternative, which could potentially provide a third revenue stream.</li></ul>Hycroft Mining (HYMC) shares rallied nearly 30% on Wednesday after it reported growth in gold and silver resources.&nbsp;The Nevada-based mining company said that it has filed a third-party, independent Technical Report updating its Mineral Resource estimate with an effective date of January 21, 2026.&nbsp;The updated assessment shows the company now holds 16.4 million gold ounces and 562.6 million silver ounces in the measured and indicated categories.<h2 class="st-heading-2">Growth In Gold And Silver&nbsp;</h2>Hycroft also reported increases in inferred mineral resources of 50% for gold and 38% for silver. The company established an initial high-grade silver resource of 90.2 million ounces in the measured and indicated categories.&nbsp;The Mineral Resource estimate is based on a flowsheet utilizing milling and pressure oxidation (POX) for sulfide and certain transition mineralization and heap leaching process for oxide and other transition mineralization."Importantly, following only approximately 14 months of drilling since the discovery of two new high-grade silver systems, a high-grade mineral resource with underground potential has been established demonstrating the continuity of both the Brimstone and Vortex high-grade systems which remain open along strike and at depth," said Diane R. Garrett, President and Chief Executive Officer.&nbsp;The company said it is continuing to evaluate a roasting process alternative, which could potentially provide a third revenue stream through the by-product production and sale of sulfuric acid needed in the lithium, copper, and fertilizer industries.&nbsp;Producing and selling sulfuric acid could essentially convert a significant neutralization cost in the POX process into a by-product revenue from the roasting process.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around HYMC trended in ‘bullish’ territory amid ‘normal’ message volume.&nbsp;One user predicted that HYMC stock will be at a minimum of $150 price levels.<stembedurl>https://stocktwits.com/Puffyk/message/645246788</stembedurl>Another user said that they are very bullish on the stock.<stembedurl>https://stocktwits.com/Mazza020/message/645241401</stembedurl>Shares in the company have rocketed nearly 1450% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

The Nevada-based mining company said that it has filed a third-party, independent Technical Report updating its Mineral Resource estimate with an effective date of January 21, 2026. 

Hycroft Mining Stock Is Rallying Today – What Is Driving Trader Sentiment?

The company said that it has filed a third-party, independent Technical Report updating its Mineral Resource estimate with an effective date of January 21, 2026.

<ul class="summary-bullets"><li>The company also said it expects $10 million to $20 million in adjusted EBITDA in FY2027.&nbsp;</li><li>The company said for the third quarter its revenue was $16.3 million versus $40.7 million in the prior-year quarter, a 60% decrease.</li><li>Direct Operating Margin was 69%, compared to 48% in the prior year quarter, reflecting the company's continued focus on cost management.&nbsp;</li></ul>Shares of Cineverse (<a href="https://stocktwits.com/symbol/CNVS">CNVS</a>) jumped on Tuesday after it posted higher-than-expected outlook for its FY 2027 revenue.&nbsp;The company said it expects $115 million to $120 million in revenue for fiscal year 2027, that commences from April 1, 2026. Analysts on average were expecting the revenue of $85.23 million, as per data from fiscal.ai.&nbsp;The company also said it expects $10 million to $20 million in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in FY2027.&nbsp;"Already, we have seen extremely positive results from the Giant acquisition over the last 6 weeks, and IndiCue's month-over-month financial performance prior to acquisition was scaling up very rapidly. Therefore, we feel very confident in the financial guidance we are issuing for Fiscal Year 2027, which begins April 1, 2026, of $115 to $120 million in Revenue and $10 to $20 million in Adjusted EBITDA," said Chris McGurk, Cineverse Chairman and CEO.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>The company said for the third quarter its revenue was $16.3 million versus $40.7 million in the prior-year quarter, a 60% decrease, due to approximately $22.8 million of theatrical revenue from Terrifier 3 in the prior year fiscal quarter. The revenue was also below analysts’ estimates of $20 million, as per data from fiscal.ai.&nbsp;Direct Operating Margin was 69%, compared to 48% in the prior year quarter, reflecting the company's continued focus on cost management.&nbsp;The company said its total streaming viewers increased approximately 10% year-over-year in Q3 FY26 to 149 million.&nbsp;The company’s net loss attributable to common stockholders was $1.0 million, or $0.05 per basic and diluted share, compared to a net profit of $7.0 million, or $0.34 per share, in the prior-year quarter. Analysts expected a loss of $0.03 per share.&nbsp;"Our financial objective during this quarter was to focus on improving operating results in our base business in anticipation of closing the transformative Giant and IndiCue acquisitions. We are very pleased that these efforts paid off, with significant increases in both Direct Operating Margins and Adjusted EBITDA,” said McGurk.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around CNVS trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen 36.4% over the past year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/new-york-times-sahres-are-rallying-what-is-the-connection-with-berkshire-hathaway/cZRWySkR4H3">NYT Stock Is Rallying After-Hours – What Is The Berkshire Hathaway Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Cineverse jumped on Tuesday after it posted higher-than-expected outlook for its FY 2027 revenue. 

Why Is Cineverse Stock Rising Despite Missing Q3 Revenue and Earnings Estimates?

The company said it expects $115 million to $120 million in revenue for fiscal year 2027, however analysts on average were expecting the revenue of $85.23 million, as per data from fiscal.ai. 

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWC News

IWCiShares Micro-Cap ETF